Compare Amylx Pharmaceuticals Inc (AMLX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vistra Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.3 (market cap $1.98B), while Vistra Corp trades at $156.89 (market cap $53.56B). The key difference: Vistra Corp is far larger — about 27.1× Amylx Pharmaceuticals Inc's market cap, and Vistra Corp pays a 0.58% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VST | |
|---|---|---|
Market Cap | $1.98B | $53.56B |
Sector | Health | Technology |
52-Week High | $18.70 | $217.92 |
52-Week Low | $7.64 | $134.71 |
Enterprise Value | $1.70B | $75.32B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Vistra Corp. (VST) trades at $158.86, up 0.56% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 estimates. Revenue grew to $19.4B in 2026 with net profit margin improving to 11.52%. Recent news highlights AI-driven power demand and long-term PPAs with Meta and AWS as growth catalysts.
Outlook is positive with 91% analyst buy ratings and a $230.50 consensus price target, implying 45% upside. Risks include execution on growth initiatives and macroeconomic volatility. The stock offers exposure to rising electricity demand and stable cash flows from utility operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
